Onconetix, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Onconetix, Inc. (ONCO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$2.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-13
- Onconetix, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$2.87M.
- Onconetix, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$4.21M.
- Onconetix, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $5.67M.
- Onconetix, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$8.78M.
- Onconetix, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$15.53M.
- Onconetix, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$58.90M.
- Onconetix, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$37.41M.
- Onconetix, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$13.52M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.87M 10-Q · filed 2026-08-13 | -$7.08M 10-Q · filed 2026-08-13 | -$1.41M derived: sum of 3 quarters · filed 2026-08-13 | -$10.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$4.21M 10-Q · filed 2026-05-13 | $1.45M derived: sum of 2 quarters · filed 2026-05-13 | -$7.33M derived: sum of 3 quarters · filed 2026-05-13 | -$10.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$3.11M derived: sum of 2 quarters · filed 2026-03-13 | -$5.81M derived: sum of 3 quarters · filed 2026-08-13 | -$15.53M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$8.78M 10-Q · filed 2025-11-13 | -$11.48M derived: sum of 2 quarters · filed 2026-08-13 | -$21.20M 10-Q · filed 2025-11-13 | -$50.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.70M 10-Q · filed 2026-08-13 | -$12.42M 10-Q · filed 2026-08-13 | -$42.06M derived: sum of 3 quarters · filed 2026-08-13 | -$45.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$9.72M 10-Q · filed 2026-05-13 | -$39.36M derived: sum of 2 quarters · filed 2026-05-13 | -$43.19M derived: sum of 3 quarters · filed 2026-05-13 | -$57.49M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$29.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$33.47M derived: sum of 2 quarters · filed 2026-03-13 | -$47.78M derived: sum of 3 quarters · filed 2026-03-13 | -$58.90M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$3.83M 10-Q · filed 2025-11-13 | -$18.13M derived: sum of 2 quarters · filed 2025-11-13 | -$29.25M 10-Q · filed 2025-11-13 | -$51.60M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$14.31M 10-Q · filed 2025-08-14 | -$25.43M 10-Q · filed 2025-08-14 | -$47.78M derived: sum of 3 quarters · filed 2025-08-14 | -$53.12M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$11.12M 10-Q · filed 2025-06-12 | -$33.47M derived: sum of 2 quarters · filed 2025-06-12 | -$38.82M derived: sum of 3 quarters · filed 2025-06-12 | -$45.68M derived: sum of 4 quarters · filed 2025-06-12 |
| 2023-12-31 | -$22.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | -$27.70M derived: sum of 2 quarters · filed 2025-06-02 | -$34.56M derived: sum of 3 quarters · filed 2025-06-02 | -$37.41M 10-K · filed 2025-06-02 |
| 2023-09-30 | -$5.35M 10-Q · filed 2023-11-17 | -$12.21M derived: sum of 2 quarters · filed 2023-11-17 | -$15.06M 10-Q · filed 2023-11-17 | -$18.28M derived: sum of 4 quarters · filed 2024-04-11 |
| 2023-06-30 | -$6.87M 10-Q · filed 2023-10-20 | -$9.71M 10-Q · filed 2023-10-20 | -$12.93M derived: sum of 3 quarters · filed 2024-04-11 | -$16.80M derived: sum of 4 quarters · filed 2024-04-11 |
| 2023-03-31 | -$2.85M 10-Q · filed 2023-05-12 | -$6.06M derived: sum of 2 quarters · filed 2024-04-11 | -$9.93M derived: sum of 3 quarters · filed 2024-04-11 | -$14.20M derived: sum of 4 quarters · filed 2024-04-11 |
| 2022-12-31 | -$3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | -$7.08M derived: sum of 2 quarters · filed 2024-04-11 | -$11.35M derived: sum of 3 quarters · filed 2024-04-11 | -$13.52M 10-K · filed 2024-04-11 |
| 2022-09-30 | -$3.87M 10-Q · filed 2023-11-17 | -$8.13M derived: sum of 2 quarters · filed 2023-11-17 | -$10.30M 10-Q · filed 2023-11-17 | -$11.67M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | -$4.26M 10-Q · filed 2023-10-20 | -$6.43M 10-Q · filed 2023-10-20 | -$7.80M derived: sum of 3 quarters · filed 2023-10-20 | -$9.08M derived: sum of 4 quarters · filed 2023-10-20 |
| 2022-03-31 | -$2.17M 10-Q · filed 2023-05-12 | -$3.53M derived: sum of 2 quarters · filed 2023-05-12 | -$4.82M derived: sum of 3 quarters · filed 2023-05-12 | -$5.75M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$2.65M derived: sum of 2 quarters · filed 2023-03-09 | -$3.58M derived: sum of 3 quarters · filed 2023-03-09 | -$4.04M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$1.28M 10-Q · filed 2022-11-14 | -$2.21M derived: sum of 2 quarters · filed 2022-11-14 | -$2.68M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$931.49K 10-Q · filed 2022-08-15 | -$1.39M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$463.47K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |